[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @biotechsanya2 SSV SSV posts on X about $ocul, $traw, $5byear, $15mil the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1715091835259887616/interactions)  - X Week XXXXX -XX% - X Month XXXXX +2,163% - X Months XXXXX +8,454% - X Year XXXXX +803% ### Mentions: X [#](/creator/twitter::1715091835259887616/posts_active)  - X Week X +200% - X Month XX +900% - X Months XX +700% - X Year XX +800% ### Followers: XXX [#](/creator/twitter::1715091835259887616/followers)  - X Week XXX +16% - X Months XXX +633% ### CreatorRank: undefined [#](/creator/twitter::1715091835259887616/influencer_rank)  ### Social Influence [#](/creator/twitter::1715091835259887616/influence) --- **Social category influence** [currencies](/list/currencies) XXXX% **Social topic influence** [$ocul](/topic/$ocul) 15.38%, [$traw](/topic/$traw) 7.69%, [$5byear](/topic/$5byear) 7.69%, [$15mil](/topic/$15mil) 7.69%, [mcap](/topic/mcap) 7.69%, [$eypt](/topic/$eypt) 7.69%, [$oculs](/topic/$oculs) 7.69%, [$450m](/topic/$450m) 7.69%, [$ifrx](/topic/$ifrx) XXXX% **Top accounts mentioned or mentioned by** [@streetcred2017](/creator/undefined) [@jeremyfalmouth](/creator/undefined) [@balabioresearch](/creator/undefined) [@plainyogurt21](/creator/undefined) [@persimmonti](/creator/undefined) [@biohazard3737](/creator/undefined) [@pikacapital](/creator/undefined) [@jfais20](/creator/undefined) ### Top Social Posts [#](/creator/twitter::1715091835259887616/posts) --- Top posts by engagements in the last XX hours "@JeremyFalmouth @BalaBioResearch its not worth the premium you have in $OCUL currently. And lol how will the debate end both products have the place in the market. Owning this after recent raise is nonsensical at least to me and I bought around $X this year out at $XXXXX they think too much of themselves" [X Link](https://x.com/biotechsanya2/status/1978222115535851907) [@biotechsanya2](/creator/x/biotechsanya2) 2025-10-14T22:11Z XXX followers, XXX engagements "$TRAW seems like an obvious play at these levels: Binary P2a readout for TRX01 which has a $5b/year TAM in Covid-19 mcap at $15mil and strong PK data from P1. Target: $1326 if P2 is successful; also is a wonderful run-up play. Will publish full report soon on Substack. If they fail this likely goes to $XXXX Disclosure: Im long TRAW; no compensation; opinion only; see bio" [X Link](https://x.com/biotechsanya2/status/1975652886093635967) [@biotechsanya2](/creator/x/biotechsanya2) 2025-10-07T20:02Z XXX followers, 3423 engagements "@BalaBioResearch it certainly isn't though. recent raise was very dilutive and completely unnecessary there is also $EYPT with an equivalent product trading at a XX% discount. not to mention how often $OCUL's managment insists upon itself rather than focusing on execution" [X Link](https://x.com/biotechsanya2/status/1978205413964218542) [@biotechsanya2](/creator/x/biotechsanya2) 2025-10-14T21:04Z XXX followers, XXX engagements "$OCUL managed to lose so much credibility recently that its honestly impressive in a way. also did mgmt ever explain the need to raise $450m or is this vibes based decision making $OCUL has to be at $6-8 for anyone to be even interested in them imho" [X Link](https://x.com/biotechsanya2/status/1978198799722954782) [@biotechsanya2](/creator/x/biotechsanya2) 2025-10-14T20:38Z XXX followers, XXX engagements "$IFRX-- I *think* the main question is: did Avacopan fail because of insufficient blockade on of C5aR OR because C5aR s not rate-limiting If INF904 is a *better* Avacopan it DOESN'T matter if the reason why Ava' failed is that C5aR blockade doesn't achieve anything due to TNF-a signalling; other "Ils" is what drives signalling-- if the case is that C5aR blockade (IFRX thinks they have a more potent Ava') IS sufficient this COULD be a win. I think the odds of this working are minimal as we know that X C5a inhibitors have already failed that being said there's a small chance this hits as this" [X Link](https://x.com/biotechsanya2/status/1978587133511184878) [@biotechsanya2](/creator/x/biotechsanya2) 2025-10-15T22:21Z XXX followers, XXX engagements "@StreetCred2017 Yes I am referring to Avas failed HS trial. Also interesting they have never tested this in CSU despite sort of similar ideation therein and pathways etc" [X Link](https://x.com/biotechsanya2/status/1978589768918200775) [@biotechsanya2](/creator/x/biotechsanya2) 2025-10-15T22:32Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@biotechsanya2 SSV
SSV posts on X about $ocul, $traw, $5byear, $15mil the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXX +2,163%
- X Months XXXXX +8,454%
- X Year XXXXX +803%
Mentions: X #
- X Week X +200%
- X Month XX +900%
- X Months XX +700%
- X Year XX +800%
Followers: XXX #
- X Week XXX +16%
- X Months XXX +633%
CreatorRank: undefined #
Social Influence #
Social category influence currencies XXXX%
Social topic influence $ocul 15.38%, $traw 7.69%, $5byear 7.69%, $15mil 7.69%, mcap 7.69%, $eypt 7.69%, $oculs 7.69%, $450m 7.69%, $ifrx XXXX%
Top accounts mentioned or mentioned by @streetcred2017 @jeremyfalmouth @balabioresearch @plainyogurt21 @persimmonti @biohazard3737 @pikacapital @jfais20
Top Social Posts #
Top posts by engagements in the last XX hours
"@JeremyFalmouth @BalaBioResearch its not worth the premium you have in $OCUL currently. And lol how will the debate end both products have the place in the market. Owning this after recent raise is nonsensical at least to me and I bought around $X this year out at $XXXXX they think too much of themselves"
X Link @biotechsanya2 2025-10-14T22:11Z XXX followers, XXX engagements
"$TRAW seems like an obvious play at these levels: Binary P2a readout for TRX01 which has a $5b/year TAM in Covid-19 mcap at $15mil and strong PK data from P1. Target: $1326 if P2 is successful; also is a wonderful run-up play. Will publish full report soon on Substack. If they fail this likely goes to $XXXX Disclosure: Im long TRAW; no compensation; opinion only; see bio"
X Link @biotechsanya2 2025-10-07T20:02Z XXX followers, 3423 engagements
"@BalaBioResearch it certainly isn't though. recent raise was very dilutive and completely unnecessary there is also $EYPT with an equivalent product trading at a XX% discount. not to mention how often $OCUL's managment insists upon itself rather than focusing on execution"
X Link @biotechsanya2 2025-10-14T21:04Z XXX followers, XXX engagements
"$OCUL managed to lose so much credibility recently that its honestly impressive in a way. also did mgmt ever explain the need to raise $450m or is this vibes based decision making $OCUL has to be at $6-8 for anyone to be even interested in them imho"
X Link @biotechsanya2 2025-10-14T20:38Z XXX followers, XXX engagements
"$IFRX-- I think the main question is: did Avacopan fail because of insufficient blockade on of C5aR OR because C5aR s not rate-limiting If INF904 is a better Avacopan it DOESN'T matter if the reason why Ava' failed is that C5aR blockade doesn't achieve anything due to TNF-a signalling; other "Ils" is what drives signalling-- if the case is that C5aR blockade (IFRX thinks they have a more potent Ava') IS sufficient this COULD be a win. I think the odds of this working are minimal as we know that X C5a inhibitors have already failed that being said there's a small chance this hits as this"
X Link @biotechsanya2 2025-10-15T22:21Z XXX followers, XXX engagements
"@StreetCred2017 Yes I am referring to Avas failed HS trial. Also interesting they have never tested this in CSU despite sort of similar ideation therein and pathways etc"
X Link @biotechsanya2 2025-10-15T22:32Z XXX followers, XX engagements